MediGene and DKFZ present data from the AAVLP vaccine program at the International Papillomavirus Conference
(Thomson Reuters ONE) -
MediGene AG /
MediGene and DKFZ present data from the AAVLP vaccine program at the
International Papillomavirus Conference
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, September 20, 2011. The biotech companyMediGene AG
(Frankfurt, Prime Standard) announces that preclinical data from its AAVLP
vaccine technology will be presented today at the 27th International
Papillomavirus Conference in Berlin. These data were generated in cooperation
with the German Cancer Research Center (DKFZ). The oral presentation titled
"Development of AAVLP (HPV16/31L2) particles as broadly protective vaccine
candidates"[1] (OP-32.01) will take place today, September 20, 2011, at 6:45 pm
in the Poster Area South of the International Congress Center in Berlin.
The presented data show that particles derived from MediGene's AAVLP vaccine
technology, which comprise peptides from human papilloma virus (HVP) serotypes
16 and 31, induce neutralizing antibodies against a broad range of HPV serotypes
in mice-vaccination studies. The in vivo studies provide evidence for the
potential of the technology for the development of a prophylactic vaccine
against infections of cancer-inducing HPV serotypes.
MediGene holds an extensive IP portfolio regarding the AAVLP technology, and is
currently conducting research into the application of AAVLP technology for the
treatment of cancer and viral infections. MediGene is also examining the
possibility of using AAV libraries for the systematic identification of suitable
vaccine candidates. The key benefit of this technology may be the possibility of
transferring the efficacy of existing therapeutic antibodies directly into a
vaccine.
MediGene' s AAVLP-based vaccine candidates have shown an excellent safety
profile in preclinical studies thus far, and may therefore constitute not only
an interesting alternative to conventional vaccines, but also significantly
widen the range of applications for vaccines against cancer and other diseases.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene® is a registered trademarks of MediGene AG. These trademarks may be
owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. MediGene is the first
German biotech company to have revenues from marketed products. It has various
drug candidates in clinical development and possesses innovative platform
technologies. MediGene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases.
About AAVLP: In its AAVLP program, which is currently at the preclinical stage,
MediGene is investigating the use of adeno-associated viruses (AAV) as a
vaccine. The adeno-associated virus is non-pathogenic, i.e. it does not cause
disease. The virus protein shell, the capsid, is suited for the production of
so-called virus-like particles (VLP), which can be used as a basis for novel
vaccines. By inserting short antigenic peptides (B-cell epitopes) into the AAV
capsid, a highly specific antibody reaction against selected target molecules
can be induced in the body. These antibodies can protect the body (i.e. have a
prophylactic effect) or act as a therapy against existing diseases.
About HPV: The term "human papillomaviruses" describesa family of viruses that
is capable of infecting the epithelium of the skin or different mucous
membranes, causing tumor-like growth. The viruses are typically transmitted
through sexual contact. Depending on the HPV type, the consequences of an
infection vary in their severity. Some particularly aggressive types of HPV are
capable of causing malignant changes, e.g. cervical cancer in women.
Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor(at)medigene.com
[1] K. Nieto, S. Sedlmeier, P. Sehr, M. Ritter, M. Weghofer, M. Hörer, U.
Michaelis, M. Müller, L. Gissmann, J. Kleinschmidt
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
press release as pdf:
http://hugin.info/132073/R/1547701/475057.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
[HUG#1547701]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Bayfield Reports 1,414.55 g/t Silver over 1.10m in Rainy River, NW OntarioDatum: 20.09.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 67372
Anzahl Zeichen: 6175
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 229 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene and DKFZ present data from the AAVLP vaccine program at the International Papillomavirus Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
